# Prophylaxis Regimen for Hemophilia A Patients

> **NCT05036278** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 21 (actual)

## Conditions studied

- Hemophilia A
- Prophylaxis of Bleeding

## Interventions

- **BIOLOGICAL:** Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).

## Key facts

- **NCT ID:** NCT05036278
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-28
- **Primary completion:** 2024-09-12
- **Final completion:** 2024-09-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036278, "Prophylaxis Regimen for Hemophilia A Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05036278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*